Intrastriatal Fyn silencing as a gene therapy strategy to manage levodopa induced dyskinesia in a mice model of Parkinson’s disease
Objective: To genetically abrogate Fyn expression to reduce levodopa induced dyskinesia (LID) in the 6-OHDA mice model of Parkinson’s disease (PD), using intrastriatal-injected lentiviral (LV)…Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010)
Objective: To assess the frequency of dyskinesias in a population based-cohort of Parkinson’s disease patients. Background: Levodopa-induced dyskinesias are complications that may impact quality of…Spatiotemporal patterns of direct and indirect pathway striatal projection neurons in mouse model of Parkinson’s disease and dyskinesia
Objective: To identify patterns of striatal projection neurons (SPN) activities that code for akinetic and dyskinetic movement disorders in a mouse model of hemiparkinsonism and…Interaction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesiaInteraction between mGluR5 and NR2B is increased in 6-OHDA parkinsonian rats with L-dopa-induced dyskinesia
Objective: In this study, we verified whether the interaction of mGluR5 and NR2B exerts an important effect on the development of LID. Background: L-dopa is…Ondansetron, a highly-selective 5-HT3 receptor antagonist, alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effectiveness of selective serotonin 3 (5-HT3) receptor blockade at reducing the severity of established, and preventing the development of, dyskinesia. Background:…Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients
Objective: This economic evaluation projects the likely cost-effectiveness of ADS-5102 in comparison to the current standard of best supportive care. Background: In August, 2017, the…Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and Parkinson’s Disease: Preliminary report
Objective: We conducted a pilot study to determine the association between the neutrophil to lymphocyte ratio (NLR), he lymphocyte to monocyte ratio (LMR), the levels…Mild to moderate dyskinesia is not significantly related to the level of activity engagement or quality of life of patients with Parkinson’s disease
Objective: This cross-sectional study aimed at determining the relation between levels of drug-induced dyskinesia (DID), tremor, rigidity, bradykinesia, postural instability, as well as cognition and…Does motor laterality affect the development of dyskinesia in patients with Parkinson’s disease?
Objective: To investigate the effects of motor laterality on the development of levodopa-induced dyskinesia (LID) in patients with de novo Parkinson’s disease (PD). Background: LID…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 40
- Next Page »